GLP-2 T

Dual GIP/GLP-1 Receptor Agonist • Lyophilized Research Peptide

GLP-2 T is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It represents a novel class of metabolic research compound that simultaneously activates two incretin hormone pathways.

The dual-agonist mechanism has generated substantial scientific interest, as simultaneous GIP and GLP-1 receptor activation appears to produce additive and potentially synergistic effects on glycemic control, weight regulation, and lipid metabolism. Published clinical literature includes large-scale trials examining outcomes in type 2 diabetes (SURPASS series) and obesity (SURMOUNT series).

GLP-2 T is supplied as a lyophilized powder at multiple concentration options, independently verified to ≥99% purity.

Receptor Targets

Dual GIP + GLP-1 Agonist

Molecular Weight

4813.48 g/mol

Form

Lyophilized Powder

Purity

≥99% by HPLC

CAS Number

2023788-19-2

Storage

−20°C lyophilized / 2–8°C reconstituted

Select Option

Lyophilized powder, sterile-filled

$45.00

Published Research

↗

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes — SURPASS-2

Frías et al. • NEJM • 2021

↗

Tirzepatide Once Weekly for the Treatment of Obesity — SURMOUNT-1

Jastreboff et al. • NEJM • 2022

↗

Tirzepatide, a GIP/GLP-1 dual receptor agonist for type 2 diabetes with and without obesity

Rosenstock et al. • Lancet Diabetes & Endocrinology • 2022

↗

Tirzepatide versus Insulin Degludec in Patients with Type 2 Diabetes — SURPASS-5

Dahl et al. • NEJM • 2023

Research Use Only. This product is not approved by the FDA for human use. All information is intended for educational and research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

Are you over 21?

GLP-2 T

Select Option

Published Research